{"id":"W3199203187","doi":"10.1161/strokeaha.121.035002","title":"Cilostazol for Secondary Stroke Prevention","year":2021,"lang":"en","type":"review","venue":"Stroke","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute","funders":"National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke; British Heart Foundation; Alzheimer's Society; National Institute of Nursing Research; National Heart, Lung, and Blood Institute","keywords":"Cilostazol; Medicine; Stroke (engine); Discontinuation; Clopidogrel; Clinical trial; Adverse effect; Aspirin; Randomized controlled trial; Internal medicine; Platelet aggregation inhibitor; Population; Placebo; Antiplatelet drug; Cardiology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002349697,0.0003812546,0.002151043,0.0001325039,0.00008552128,0.00003559227,0.0001224347,0.0003505682,0.0006852571],"category_scores_gemma":[0.00005870251,0.0003221133,0.004391216,0.0001105926,0.00004379893,0.00005388748,0.00004464246,0.0003651442,0.00005855378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008673926,"about_ca_system_score_gemma":0.001057673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001135264,"about_ca_topic_score_gemma":0.000001093347,"domain_scores_codex":[0.9982818,0.0001243461,0.0004607806,0.0004989517,0.0003140857,0.0003200173],"domain_scores_gemma":[0.9988534,0.00008259789,0.0001773627,0.000606751,0.0001172185,0.0001626193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003371635,0.00008956691,0.000002321459,0.01551363,0.003928239,0.00007558181,0.000006012922,5.538644e-8,0.00000185264,0.0001269451,0.00278937,0.9774327],"study_design_scores_gemma":[0.001293662,0.0002150157,0.000003522576,0.00884915,0.008681077,0.000204552,0.00003855654,5.270601e-7,0.00001885273,0.00001784228,0.9804106,0.0002666673],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001877062,0.9917621,0.0009288313,0.00001634769,0.0003947317,0.001850283,0.001243083,0.0000746674,0.003711203],"genre_scores_gemma":[0.000006312914,0.9699596,0.0004872555,0.00006641566,0.000874111,0.0003560527,0.002546608,0.00008916414,0.02561446],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9776212,"threshold_uncertainty_score":0.9999231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04892344570305177,"score_gpt":0.3537345861671592,"score_spread":0.3048111404641075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}